192 related articles for article (PubMed ID: 38228719)
1. Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network.
Larid G; Baudens G; Tiemdjo-Djimaffo G; Coquerelle P; Goeb V; Guyot MH; Marguerie L; Maury F; Veillard E; Houvenagel E; Salmon JH; Flipo RM; Gervais E
Sci Rep; 2024 Jan; 14(1):1374. PubMed ID: 38228719
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
3. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
[TBL] [Abstract][Full Text] [Related]
4. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
Lund Hansen R; Schoedt Jørgensen T; Dreyer L; Hetland ML; Glintborg B; Askling J; Di Giuseppe D; Jacobsson LTH; Wallman JK; Nordstrom D; Aaltonen K; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Love TJ; Kristensen LE
Rheumatology (Oxford); 2021 Jan; 60(1):140-146. PubMed ID: 32591790
[TBL] [Abstract][Full Text] [Related]
6. Tapering biologics in axial spondyloarthritis: A systematic literature review.
Saoussen M; Yasmine M; Lilia N; Alia F; Hiba B; Kawther BA; Ahmed L
Int Immunopharmacol; 2022 Nov; 112():109256. PubMed ID: 36150228
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.
Bekele DI; Cheng E; Reimold A; Geier C; Ganuthula K; Walsh JA; Clegg DO; Dubreuil M; Kaushik P; Ng B; Chang E; Duong R; Park J; Kerr GS
Rheumatol Int; 2022 Nov; 42(11):1925-1937. PubMed ID: 34724089
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
Baraliakos X; Witte T; De Clerck L; Frediani B; Collantes-Estévez E; Katsifis G; VanLunen B; Kleine E; Hoepken B; Bauer L; Goodson N
Rheumatology (Oxford); 2021 Jan; 60(1):113-124. PubMed ID: 32584415
[TBL] [Abstract][Full Text] [Related]
9. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
10. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.
Yahya F; Gaffney K; Hamilton L; Lonsdale E; Leeder J; Brooksby A; Cavill C; Berry-Jenkins J; Boyle C; Bond D; Sengupta R;
Rheumatology (Oxford); 2018 Apr; 57(4):619-624. PubMed ID: 29272541
[TBL] [Abstract][Full Text] [Related]
11. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol for treating axial spondyloarthritis.
Desmarais J; Beier S; Deodhar A
Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
[TBL] [Abstract][Full Text] [Related]
13. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
[TBL] [Abstract][Full Text] [Related]
14. Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Flouri I; Goutakoli P; Repa A; Bertsias A; Avgoustidis N; Eskitzis A; Pitsigavdaki S; Kalogiannaki E; Terizaki M; Bertsias G; Sidiropoulos P
Rheumatol Int; 2024 Feb; 44(2):249-261. PubMed ID: 37815625
[TBL] [Abstract][Full Text] [Related]
15. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
16. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
van der Horst-Bruinsma I; van Bentum R; Verbraak FD; Rath T; Rosenbaum JT; Misterska-Skora M; Hoepken B; Irvin-Sellers O; VanLunen B; Bauer L; Rudwaleit M
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371433
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.
Olivieri I; Fanizza C; Gilio M; Ravasio R
Clin Exp Rheumatol; 2016; 34(5):935-940. PubMed ID: 27385374
[TBL] [Abstract][Full Text] [Related]
18. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.
Baraliakos X; Kruse S; Auteri SE; de Peyrecave N; Nurminen T; Kumke T; Hoepken B; Braun J
Rheumatology (Oxford); 2022 Jul; 61(7):2875-2885. PubMed ID: 34791107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
